Lars Paeger
Has grant
Principal Investigator, Head of In vivo Electrophysiology Laboratory
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Mitochondria determine tau selective vulnerability of the Locus Coeruleus in AD
Open Date: 2026-01-01
Close Date: 2028-12-01
Grant: Close
Spatiotemporally resolved microglial diversity and reciprocal interaction with the noradrenergic system in Alzheimer’s disease
Open Date: 2025-01-01
Close Date:
Grant: Close
The role of TSPO expression in neurons, microglia, and the noradrenergic system following acute and chronic stress
Open Date: 2023-01-01
Close Date:
Grant: Close
The central control of growth hormone release – electrophysiology and functional role of neuroendocrine somatostatin neurons
Open Date: 2019-01-01
Close Date: 2020-12-01
Articles (10)
Stem-cell-based in vitro models offer promising potential to elucidate human brain cell functions and interactions under physiological and pathological conditions. However, harnessing this potential is impaired by low reproducibility, maturity, or cell-type diversity of existing models. Especially, prolonged incorporation of mature microglia and studies of neuroinflammation have proven challenging. Here, we developed a 3D cortical brain tissue model (3BTM) containing neurons, astrocytes, and microglia with high reproducibility, maturity, and viability. 3BTMs show morphological, functional, and proteomic maturation of all cell types, leading to high similarity to their in vivo counterparts. Incorporated microglia survive for over 6 months and display mature morphology, functions, and gene expression. Importantly, when engineered to model Alzheimer’s disease pathology, 3BTMs recapitulate key disease hallmarks including amyloid deposition, increased phospho-Tau levels, and neuroinflammation, with microglia shifting their transcriptional landscape to disease-relevant signatures. Together, our model offers unprecedented possibilities for studying physiological and pathological states of human brain tissue and translational applications.
Year:
2026
Alzheimer’s disease (AD) often begins with non-cognitive symptoms such as olfactory deficits, which can predict later cognitive decline, though the mechanisms remain unclear. Pathologically, the brainstem locus coeruleus (LC), the main source of the neurotransmitter noradrenalin (NA) modulating olfactory information processing is affected early. Here we show early and distinct loss of noradrenergic input to the olfactory bulb (OB) coinciding with impaired olfaction in an AD mouse model, before appearance of amyloid plaques. Mechanistically, OB microglia recognize and phagocytose LC axons. Reducing phagocytosis genetically preserves LC axons and olfaction. Prodromal AD patients display elevated TSPO-PET signals in the OB, similarly to App NL-G-F mice. We further confirm early LC axon degeneration in post-mortem OBs in patients with early AD. Our findings reveal a mechanism linking early LC damage to hyposmia in AD, suggesting olfactory testing and neurocircuit imaging for early diagnosis and enable timely therapeutic intervention for Alzheimer’s disease.
Year:
2025
Mitochondria are the primary energy producing organelles in eukaryotic cells. Their location is tied to the cell compartment’s energy requirement. Whether mitochondria are actively transported and retain their motility in neuronal axons of adult animals remains debated. Here we show not only a higher fraction of motile axonal mitochondria than currently described, but also marked differences in transport dynamics across neuronal subtypes. We further show that aggregated tau in the Locus Coeruleus (LC), an early pathological hallmark of Alzheimer’s disease, impairs mitochondrial transport along axons, an effect absent in cortical inhibitory and excitatory neurons. Collectively, we demonstrate the abundant and diverse motility of neuronal mitochondria in vivo , and reveal a correlate of LC vulnerability to tau proteinopathy in neurodegenerative diseases.
Year:
2025
Niemann-Pick type C (NPC) disease is an inherited lysosomal storage disorder mainly driven by mutations in the NPC1 gene, causing lipid accumulation within late endosomes/lysosomes and resulting in progressive neurodegeneration. Although microglial activation precedes neuronal loss, it remains elusive whether loss of the membrane protein NPC1 in microglia actively contributes to NPC pathology. In a mouse model with depletion of NPC1 in myeloid cells, we report severe alterations in microglial lipidomic profiles, including the enrichment of bis(monoacylglycero)phosphate, increased cholesterol, and a decrease in cholesteryl esters. Lipid dyshomeostasis was associated with microglial hyperactivity, marked by an increase in translocator protein 18 kDa (TSPO). These hyperactive microglia initiated a pathological cascade resembling NPC-like phenotypes, including a shortened life span, motor impairments, astrogliosis, neuroaxonal pathology, and increased neurofilament light chain (NF-L), a neuronal injury biomarker. As observed in the mouse model, patients with NPC showed increased NF-L in the blood and microglial hyperactivity, as visualized by TSPO-PET imaging. Reduced TSPO expression in blood-derived macrophages of patients with NPC was measured after N -acetyl- l -leucine treatment, which has been recently shown to have beneficial effects in patients with NPC, suggesting that TSPO is a potential marker to monitor therapeutic interventions for NPC. Conclusively, these results demonstrate that myeloid dysfunction, driven by the loss of NPC1, contributes to NPC disease and should be further investigated for therapeutic targeting and disease monitoring.
Year:
2024
Background Microglial activation is one hallmark of Alzheimer disease (AD) neuropathology but the impact of the regional interplay of microglia cells in the brain is poorly understood. We hypothesized that microglial activation is regionally synchronized in the healthy brain but experiences regional desynchronization with ongoing neurodegenerative disease. We addressed the existence of a microglia connectome and investigated microglial desynchronization as an AD biomarker. Methods To validate the concept, we performed microglia depletion in mice to test whether interregional correlation coefficients (ICCs) of 18 kDa translocator protein (TSPO)-PET change when microglia are cleared. Next, we evaluated the influence of dysfunctional microglia and AD pathophysiology on TSPO-PET ICCs in the mouse brain, followed by translation to a human AD-continuum dataset. We correlated a personalized microglia desynchronization index with cognitive performance. Finally, we performed single-cell radiotracing (scRadiotracing) in mice to ensure the microglial source of the measured desynchronization. Results Microglia-depleted mice showed a strong ICC reduction in all brain compartments, indicating microglia-specific desynchronization. AD mouse models demonstrated significant reductions of microglial synchronicity, associated with increasing variability of cellular radiotracer uptake in pathologically altered brain regions. Humans within the AD-continuum indicated a stage-depended reduction of microglia synchronicity associated with cognitive decline. scRadiotracing in mice showed that the increased TSPO signal was attributed to microglia. Conclusion Using TSPO-PET imaging of mice with depleted microglia and scRadiotracing in an amyloid model, we provide first evidence that a microglia connectome can be assessed in the mouse brain. Microglia synchronicity is closely associated with cognitive decline in AD and could serve as an independent personalized biomarker for disease progression.
Year:
2024
Tau PET has attracted increasing interest as an imaging biomarker for 4-repeat (4R)-tauopathy progressive supranuclear palsy (PSP). However, the translation of in vitro 4R-tau binding to in vivo tau PET signals is still unclear. Therefore, we performed a translational study using a broad spectrum of advanced methodologies to investigate the sources of [ 18 F]PI-2620 tau PET signals in individuals with 4R-tauopathies, including a pilot PET autopsy study in patients. First, we conducted a longitudinal [ 18 F]PI-2620 PET/MRI study in a 4-repeat-tau mouse model (PS19) and detected elevated [ 18 F]PI-2620 PET signals in the presence of high levels of neuronal tau. An innovative approach involving cell sorting after radiotracer injection in vivo revealed higher tracer uptake in single neurons than in the astrocytes of PS19 mice. Regional [ 18 F]PI-2620 tau PET signals during the lifetime correlated with the abundance of fibrillary tau and with autoradiography signal intensity in PSP patients and disease controls who underwent autopsy 2–63 months after tau PET. In autoradiography, tau-positive neurons and oligodendrocytes with a high AT8 density, but not tau-positive astrocytes, were the drivers of [ 18 F]PI-2620 autoradiography signals in individuals with PSP. The high tau abundance in oligodendrocytes at the boundary of gray and white matter facilitated the identification of an optimized frontal lobe target region to detect the tau burden in patients with PSP. In summary, neuronal and oligodendroglial tau constitutes the dominant source of tau PET radiotracer binding in 4-repeat-tauopathies, translating to an in vivo signal.
Year:
2024
Year:
2024
Alzheimer’s disease (AD) is often accompanied by early non-cognitive symptoms, including olfactory deficits, such as hyposmia and anosmia 1 . These have emerged as solid predictors of cognitive decline, but the underlying mechanisms of hyposmia in early AD remain elusive 2 . Pathologically, one of the brain regions affected earliest is the brainstem locus coeruleus (LC), the main source of the neurotransmitter noradrenalin (NA) and, a well-known neuromodulator of olfactory information processing 3 . Here we show that early and distinct loss of noradrenergic input to the olfactory bulb (OB) coincides with impaired olfaction in a mouse model of AD, even before pronounced appearance of extracellular amyloid plaques. Mechanistically, OB microglia detect externalized phosphatidylserine and MFG-E8 on hyperactive LC axons and subsequently initiate their clearance. Translocator protein 18 kDa (TSPO) knockout reduces phagocytosis, preserving LC axons and olfaction. Importantly, patients with prodromal AD display elevated TSPO-PET signals in the OB, similarly to APP NL-G-F mice. We further confirm early LC axon degeneration in post-mortem OBs in patients with early AD. Collectively, we uncover an underlying mechanism linking early LC system damage and hyposmia in AD. Our work may help to improve early diagnosis of AD by olfactory testing and neurocircuit analysis and consequently enable early intervention.
Year:
2024
Year:
2023
Year:
2023
Collaborators (12)
Jonas Neher
Group Leader
Hertie Institute for clinical brain research
Martina Schifferer
Nanoscale Hub group leader
Deutsches Zentrum für Neurodegenerative Erkrankungen
Stefan Lichtenthaler
Technical University of Munich
Joachim Schultze
Deutsches Zentrum für Neurodegenerative Erkrankungen
Silvia Cappello
Associate Professor
Ludwig-Maximilians-Universität München
Nikolaus Plesnila
Principal investigator
LMU University Hospital
Robert Perneczky
Professor
Ludwig-Maximilians-Universität München
Marc D Beyer
Deutsches Zentrum für Neurodegenerative Erkrankungen
Jochen Herms
Full professor
Ludwig-Maximilians-Universität München
Sophia Stoecklein
LMU University Hospital
Antje Grosche
Professor
Ludwig-Maximilians-Universität München
Dominik Paquet
Professor of Neurobiology
University Hospital, LMU Munich
Make your next move.
Prepare your application
Review drafts before you send them.